Comparison of CNS-leukaemia in children with acute leukaemia, induced either with rubidomycin or L-asparaginase.
D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D011239:Prednisolone; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin